Furthermore, although the current standard treatment for RAS wild-type left-sided metastatic CRC is chemotherapy plus an anti-EGFR antibody, our analysis revealed that patients who did not achieve early tumor shrinkage had worse overall survival, PFS, and postprogression survival compared with patients treated with chemotherapy plus bevacizumab. This evidence concerns the gene EGFR and neoplasm.